BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20855666)

  • 21. HORIZONS trial: a step forward for primary percutaneous coronary intervention.
    White HD
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):125-9. PubMed ID: 19210208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Lopes RD; Alexander KP; Manoukian SV; Bertrand ME; Feit F; White HD; Pollack CV; Hoekstra J; Gersh BJ; Stone GW; Ohman EM
    J Am Coll Cardiol; 2009 Mar; 53(12):1021-30. PubMed ID: 19298914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The HEAT-PPCI study].
    Saia F; Dall'Ara G; Calabrò P
    G Ital Cardiol (Rome); 2015 Feb; 16(2):65-70. PubMed ID: 25805088
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Parodi G; Antoniucci D; Nikolsky E; Witzenbichler B; Guagliumi G; Peruga JZ; Stuckey T; Dudek D; Kornowski R; Hartmann F; Lansky AJ; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2010 Aug; 3(8):796-802. PubMed ID: 20723849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Commentary: bivalirudin is a safe and effective anticoagulant in the percutaneous treatment of complex infrainguinal disease.
    Walker CM
    J Endovasc Ther; 2010 Feb; 17(1):37-8. PubMed ID: 20199264
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
    Mishkel GJ; Moore AL; Markwell SJ; Ligon RW
    J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
    J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
    N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
    Gibson CM; Ten Y; Murphy SA; Ciaglo LN; Southard MC; Lincoff AM; Waksman R
    Am J Cardiol; 2007 Jun; 99(12):1687-90. PubMed ID: 17560876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
    Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ;
    Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulation during percutaneous coronary intervention in diabetics--is simpler always better?
    Meier P; Gurm HS
    J Invasive Cardiol; 2010 Mar; 22(3):101-2. PubMed ID: 20197574
    [No Abstract]   [Full Text] [Related]  

  • 37. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
    Iijima R; Ndrepepa G; Mehilli J; Byrne RA; Schulz S; Neumann FJ; Richardt G; Berger PB; Schömig A; Kastrati A
    Eur Heart J; 2009 Feb; 30(3):290-6. PubMed ID: 19147609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why we do what we do? Making sense of antithrombotic therapy in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Brener SJ
    JACC Cardiovasc Interv; 2010 Jun; 3(6):678-9. PubMed ID: 20630462
    [No Abstract]   [Full Text] [Related]  

  • 39. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
    Kereiakes DJ
    Rev Cardiovasc Med; 2009; 10(2):72-82. PubMed ID: 19593319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of bivalirudin for percutaneous coronary intervention with rotational atherectomy.
    Delhaye C; Wakabayashi K; Maluenda G; Ben-Dor I; Torguson R; Xue Z; Suddath WO; Satler LF; Pichard AD; Kent KM; Lindsay J; Waksman R
    J Interv Cardiol; 2010 Jun; 23(3):223-9. PubMed ID: 20636842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.